About 70% of people on Earth carry a genetic variant that raises their risk of lupus, a severe autoimmune disease that can leave patients with debilitating fatigue, fevers, and joint pain. That's an unusually high frequency for something that harms the people who carry it, and it raises an obvious evolutionary puzzle: why hasn't natural selection weeded it out?

A study published September 11, 2026, in The American Journal of Human Genetics offers an answer. Researchers at Cincinnati Children's Hospital Medical Center found that the same variant driving up lupus risk also appears to strengthen the immune system's ability to fight off viruses, a trade-off that may explain why evolution has let a harmful gene spread so widely instead of eliminating it.

The gene at the center of the puzzle

The research team, led by Leah Kottyan, Matthew Weirauch, and Stephen Waggoner, focused on a common lupus-associated genetic haplotype tied to IRF7, short for interferon regulatory factor 7. IRF7 is a transcription factor, meaning it controls whether other genes get switched on, and its specific job sits at the center of the body's antiviral defenses.

When a cell detects foreign genetic material, a telltale sign of viral infection, IRF7 responds by binding to the cell's DNA and helping trigger production of type 1 interferons, a family of signaling proteins that rally the wider immune system into action. People with lupus tend to have elevated interferon levels circulating in their blood, and certain versions of IRF7 have long been linked to higher disease risk. On the flip side, people who lack functional copies of IRF7 appear more vulnerable to viral infections, including SARS-CoV-2, according to the study background reported by Science.

Testing the trade-off across mice, cells, and thousands of years

Kottyan's team built their case in layers. They started by analyzing genetic data from a large international study covering thousands of participants, looking for patterns connecting the lupus-risk version of IRF7 to viral infection outcomes. From there, the researchers moved into laboratory experiments using both mouse models and human cells, testing directly how the different genetic variants affected interferon production and antiviral response strength.

The result, according to Science's coverage of the findings, showed the lupus-associated variant specifically elevates type 1 interferon signaling, and that elevated signaling cuts both ways: it raises lupus risk while also sharpening the immune system's response to viral threats. Evolutionary immunologist Tobias Lenz, who wasn't involved in the research, described the finding as convincing evidence of that dual effect, according to Science's reporting.

Why this makes sense from an evolutionary standpoint

A gene that trades a rare, severe downside for a common, life-saving upside is exactly the kind of variant evolutionary biology predicts should persist and spread widely, even when it causes real harm to the smaller subset of people who go on to develop the associated disease. Viral infections have killed enormous numbers of people throughout human history, while lupus, though serious, affects a much smaller fraction of the population that carries the associated genetic variants.

That imbalance, common lethal threat versus rarer chronic disease, is a classic setup for what evolutionary biologists call balancing selection, where a trait that's costly for some carriers persists in a population because it delivers a survival advantage broadly. This isn't the first time researchers have found this kind of split effect tied to lupus genetics; earlier research out of King's College London had already linked a different lupus-associated gene, TYK2, to protection against severe COVID-19 outcomes, suggesting the pattern may run deeper than just one gene.

What this means for how lupus itself gets understood

Genetics has always played a major role in who develops lupus, and researchers have identified many of the genetic regions tied to disease risk over the years. What's been missing is a clear explanation for why those risk variants remain so genetically common rather than fading out over generations, the way most purely harmful mutations eventually do.

Kottyan's study reframes IRF7 not as a simple design flaw in the immune system, but as a calibrated trade-off, tuned by evolutionary pressure toward stronger antiviral defense at the cost of elevated autoimmune risk for a subset of carriers. That reframing matters for how researchers think about treating lupus going forward. A therapy that simply dials down interferon signaling across the board might ease autoimmune symptoms while quietly weakening a patient's ability to fight off future viral infections, a trade-off clinicians would want to understand clearly before leaning on that approach.

Where the research goes from here

The study doesn't resolve every question about IRF7's dual role. Researchers still need to work out exactly how much added viral protection the variant provides in real-world populations, and whether that protective effect varies meaningfully across different viral threats or across different genetic backgrounds worldwide. There's also the harder clinical question of whether future lupus treatments could someday be designed to preserve the antiviral benefit of elevated interferon signaling while suppressing the autoimmune consequences, rather than trading away one for the other entirely.

For now, the finding adds a genuinely satisfying explanation to a question that's puzzled geneticists for years: not why a harmful variant exists, but why the immune system apparently decided the trade was worth making in the first place.